Chimeric antigen receptors comprising CD30-derived intracellular signaling domain, immune cells expressing chimeric
By introducing the TRAF binding site in the CD30 domain as an intracellular signaling domain in CAR-T cells, the problem of poor efficacy of CAR-T cells in the treatment of solid tumors is solved, and the proliferation and survival ability of cells is improved. The cytokine secretion ability significantly enhances the lethality of solid tumors.
Patent Information
- Application Number
- CN202380022590.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-01
AI Technical Summary
The existing CAR-T cell therapy has poor therapeutic effects on solid tumors, mainly due to the limited ability of CAR-T cells to proliferate and survive in the body, making it difficult to effectively reach and destroy the immunosuppressed tumor microenvironment.
A chimeric antigen receptor was designed, including the target antigen binding domain, the transmembrane domain and CD30-derived intracellular signaling domain, especially using the TRAF binding site in the CD30 domain as the intracellular signaling structure to improve the proliferation and survival ability of immune effector cells and cytokine secretion ability.
By using TRAF binding sites in the CD30 domain, the anti-tumor efficacy and cytokine secretion of CAR-T cells were significantly improved, and the killing ability of solid tumors was enhanced.
Smart Images

Figure CN118891284A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a chimeric antigen receptor comprising a CD30-derived intracellular signaling domain, an immune cell expressing the chimeric antigen receptor, and uses thereof. Background Art
[0002] Over the past few decades, surgery, radiotherapy, chemotherapy, etc. have been developed as methods for treating cancer, but they have also shown limitations, such as severe side effects and drug resistance caused by mutations. Recently, immune checkpoint inhibitors, adaptive immune cell therapy, etc. have attracted attention as promising cancer treatment methods.
[0003] Chimeric antigen receptor (CAR)-T cell therapy is a treatment method in which cytotoxic T cells are removed from the body, genetically modified to express CARs that can recognize specific antigens, and reintroduced into the body. In this way, antigens expressed by cancer cells (but not limited to the major histocompatibility complex (MHC)) can be recognized and selectively killed. CAR consists of a single-chain variable fragment (scFv) that can recognize a specific antigen, a spacer domain, a transmembrane domain, and an intracellular signaling domain that transmits T cell activation signals.
[0004] The first generation of CAR consists of scFv and a single intracellular signaling domain that recognizes the antigen, and uses the main signaling chain CD3ζ of the T cell receptor (TCR) or the signaling chain FcR-γ of the activated Fc receptor as the signaling domain. However, the first generation of CAR-T cells lacks clinical efficacy due to its limited proliferation and survival ability in vivo. In order to overcome this problem, a second generation of CAR formed by adding a signaling region of a co-stimulatory receptor (such as CD28, 4-1BB, ICOS, OX40, and CD27) to CD3ζ was developed, as well as a third generation of CAR formed by combining two different types of co-stimulatory domains. The second and third generation CARs show improved anti-cancer effects by active proliferation and long-term survival in vivo. In addition, in order to further improve the effect on solid tumors, the fourth generation CAR or the fifth generation CAR are being studied continuously. The fourth generation CAR is based on the second or third generation CAR and co-expresses cytokines or co-stimulatory ligands that contribute to T cell activation, and the fifth generation CAR includes the technology of inhibiting human leukocyte antigen (HLA) or TCR genes.
[0005] In order to improve the efficacy of CAR-T cells, research is underway to optimize the domains that make up CAR. In particular, it is known that the costimulatory domain plays an important role in CAR-T cell proliferation, expansion, maintenance, anti-tumor activity, cytokine secretion, etc. Commonly used costimulatory domains include the immunoglobulin (Ig) superfamily, such as CD28 and ICOS (CD278), and the tumor necrosis factor receptor (TNFR) superfamily, including 4-1BB (CD137), OX40 (CD134), and CD27. The Ig superfamily costimulatory domain activates phosphatidylinositol 3-kinase (PI3K), which then activates protein kinase B (Akt) and nuclear factor κB (NF-κB) signaling pathways. On the other hand, the TNFR superfamily costimulatory domain activates the NF-κB signaling pathway through various types of TNF receptor-associated factors (TRAFs).
[0006] As a conventional CAR-T cell therapy, CAR-T cell therapy targeting human CD19 has shown impressive therapeutic effects on blood cancers such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and non-Hodgkin's lymphoma, but has poor effects on solid cancers. This is because CAR-T cells lack persistence in the body and have difficulty reaching solid tumors (transportation), which are surrounded by an immunosuppressive tumor microenvironment.
[0007] Therefore, a strategy that can increase the proliferation and survival of CAR-T cells in vivo is needed to achieve excellent therapeutic effects even against solid tumors. Summary of the invention
[0008] The object of the present invention is to provide a chimeric antigen receptor and its use which can improve the anti-tumor efficacy and cytokine secretion ability.
[0009] To achieve the above objectives, the present invention provides a chimeric antigen receptor comprising: a target antigen binding domain; a transmembrane domain; a C30-derived intracellular signaling domain comprising one or more amino acid sequences selected from the group consisting of SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48 and SEQ ID NO:50; and a CD3ζ intracellular signaling domain.
[0010] The present invention also provides a nucleic acid molecule encoding the chimeric antigen receptor.
[0011] The present invention also provides a vector comprising the nucleic acid molecule.
[0012] The present invention also provides an isolated immune effector cell, which comprises the chimeric antigen receptor, a nucleic acid molecule encoding the chimeric antigen receptor, or a vector comprising the nucleic acid molecule.
[0013] The present invention also provides an anti-tumor composition comprising the immune effector cells.
[0014] The present invention also provides a method for treating cancer, comprising administering a therapeutically effective amount of the immune effector cells to a subject in need thereof.
[0015] The present invention increases the proliferation and survival of immune effector cells by using a chimeric antigen receptor comprising a partial sequence of the TRAF binding site in the CD30 domain as an intracellular signal transduction domain, thereby having the effect of enhancing anti-tumor efficacy and cytokine secretion capacity. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1a CD19-28-z, CD19-30L-z, CD19-30M-z, CD19-30M-z according to one embodiment of the present invention are shown. mut Schematic diagram of the CD19-30-z, CD19-30ΔM-z, and CD19-30S-z CAR structures.
[0017] Figure 1b Figure 2 shows the human blood cancer cell line U937 analyzed by flow cytometry based on isotype (grey area) according to one embodiment of the present invention. mock 、U937 CD19 , IM-9 and Raji expression levels of human CD19 antigen (red area).
[0018] Figure 1c The results show that, according to one embodiment of the present invention, based on the group without CAR introduction (NT, blue area), the introduction of CD19-28-z, CD19-30L-z, CD19-30M-z, CD19-30M mut Expression levels of each CAR (red area) in KHYG-1, NK-92, αβT, and γδT cells of CD19-30-z, CD19-30ΔM-z, and CD19-30S-z CARs.
[0019] Figure 1d The invention shows that CD19-28-z, CD19-30L-z, CD19-30M-z, CD19-30M-z were introduced at various E / T ratios according to one embodiment of the invention. mut Cytolytic activity of KHYG-1, NK-92, αβT, and γδT cells expressing CD19-z, CD19-30ΔM-z, and CD19-30S-z CARs against CD19-positive and -negative human hematologic cancer cell lines, respectively.
[0020] Figure 2aCD19-30S-z, CD19-30ΔS-z, CD19-30ΔS-z, according to one embodiment of the present invention are shown. YN -z and CD19-30ΔS YF -z Schematic diagram of the CAR structure.
[0021] Figure 2b The figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with CD19-28-z, CD19-30L-z, CD19-30S-z and CD19-30ΔS-z CARs, analyzed by flow cytometry, based on the group without CAR introduction (NT, blue area) according to one embodiment of the present invention.
[0022] Figure 2c The cytolytic activities of αβT and γδT cells introduced with CD19-28-z, CD19-30L-z, CD19-30S-z and CD19-30ΔS-z CARs at various E / T ratios against CD19-positive and negative human blood cancer cell lines, respectively, are shown according to one embodiment of the present invention.
[0023] Figure 2d The results show that according to one embodiment of the present invention, based on the group without CAR introduction (NT, blue area), the introduction of CD19-28-z, CD19-30S-z, CD19-30ΔS YN -z and CD19-30Δ YF -z CAR expression levels of each CAR (red area) in αβT and γδT cells.
[0024] Figure 2e The results show that CD19-28-z, CD19-30S-z, CD19-30ΔS-z and CD19-30ΔS-z were introduced at various E / T ratios according to one embodiment of the present invention. YN -z and CD19-30Δ YF -z CAR αβT and γδT cells' cytolytic activity against CD19-positive and -negative human hematologic cancer cell lines, respectively.
[0025] Figure 3a Schematic diagrams of CD19-28-z, CD19-ICOS-z, CD19-4-1BB-z, CD19-OX40-z, CD19-27-z and CD19-30S-z CAR structures according to one embodiment of the present invention are shown.
[0026] Figure 3bThe figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with CD19-28-z, CD19-ICOS-z, CD19-4-1BB-z, CD19-OX40-z, CD19-27-z and CD19-30S-z CARs, analyzed by flow cytometry based on the group without CAR introduction (NT, blue area) according to one embodiment of the present invention.
[0027] Figure 3c The figures show the cytolytic activities of αβT and γδT cells introduced with Ig receptor family CD19-28-z and CD19-ICOS-z CARs at various E / T ratios against CD19-positive and negative human cancer cell lines, respectively, and the cytolytic activities of αβT and γδT cells introduced with CD19-30S-z CAR, respectively, according to one embodiment of the present invention.
[0028] Figure 3d The figures show the cytolytic activities of αβT and γδT cells introduced with CD19-4-1BB-z, CD19-OX40-z and CD19-27-z CARs of the TNFR family at various E / T ratios against CD19-positive and negative blood cancer cell lines, respectively, and the cytolytic activities of αβT and γδT cells introduced with CD19-30S-z CAR, respectively, according to one embodiment of the present invention.
[0029] Figure 3e The present invention shows that according to one embodiment of the present invention, the αβT cells and γδT cells introduced with CD19-28-z, CD19-4-1BB-z and CD19-30S-z CARs can be used to suppress the expression of CD19-negative U937 in αβT cells and γδT cells. mock and positive U937 CD19 The secretion levels of cytokines INF-γ, TNF-α, granzyme A, granzyme B and perforin at an E / T ratio of 1.
[0030] Figure 4a Schematic diagrams of CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z and CD19-30S-27-z CAR structures according to one embodiment of the present invention are shown.
[0031] Figure 4bThe figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z and CD19-30S-27-z CARs, analyzed by flow cytometry based on the group without introduced CAR (NT, blue area) according to one embodiment of the present invention.
[0032] Figure 4c The cytolytic activity of αβT and γδT cells introduced with CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z and CD19-30S-27-zCARs at various E / T ratios against CD19-positive and negative human blood cancer cell lines, respectively, is shown according to one embodiment of the present invention.
[0033] Figure 4d The present invention shows that according to one embodiment of the present invention, the αβT cells and γδT cells introduced with CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z and CD19-30S-27-z CARs are resistant to CD19 negative U937. mock and positive U937 CD19 The secretion levels of cytokines INF-γ, TNF-α, granzyme A, granzyme B and perforin at an E / T ratio of 1.
[0034] Figure 5a Schematic diagram of BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z CAR structures according to one embodiment of the present invention is shown.
[0035] Figure 5b Shown is the expression level of human BCMA antigen (red area) in human blood cancer cell lines U937, IM-9 and Daudi analyzed by flow cytometry based on isotype (grey area) according to one embodiment of the present invention.
[0036] Figure 5c The figure shows the expression level of each CAR (red area) in γδT cells introduced with BCMA-28-BB-z, BCMA-30S-BB-z and BCMA-28-30S-z CARs, analyzed by flow cytometry, based on the group without CAR introduction (NT, blue area) according to one embodiment of the present invention.
[0037] Figure 5d The cytolytic activity of γδ T cells introduced with BCMA-28-BB-z, BCMA-30S-BB-z and BCMA-28-30S-z CARs at various E / T ratios against BCMA-positive and negative human cancer cell lines is shown according to one embodiment of the present invention.
[0038] Figure 6a Schematic representation of EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z and EpCAM-28™ CAR structures according to one embodiment of the present invention is shown.
[0039] Figure 6b Shown is the expression level of human EpCAM antigen (red area) in human lung cancer cell lines A549, Calu-1, NCI-H292 and NCI-H460 analyzed by flow cytometry based on isotype (grey area) according to one embodiment of the present invention.
[0040] Figure 6c The figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z and EpCAM-28TM CAR, analyzed by flow cytometry, based on the group without introduced CAR (NT, blue area) according to one embodiment of the present invention.
[0041] Figure 6d The figure shows the cytolytic activity of αβT and γδT cells introduced with EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z and EpCAM-28TM CAR, respectively, against EpCAM-positive human lung cancer cell lines at various E / T ratios according to one embodiment of the present invention.
[0042] Figure 6e A schematic diagram of the EpCAM-28-BB-z, EpCAM-30S-BB-z and EpCAM-28-30S-z CAR structures according to one embodiment of the present invention is shown.
[0043] Figure 6f The figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with EpCAM-28-BB-z, EpCAM-30S-BB-z and EpCAM-28-30S-z CARs, analyzed by flow cytometry, based on the group without the introduction of CAR (NT, blue area) according to one embodiment of the present invention.
[0044] Figure 6gThe cytolytic activity of αβT and γδT cells introduced with EpCAM-28-BB-z, EpCAM-30S-BB-z and EpCAM-28-30S-z CARs at various E / T ratios against EpCAM-positive human lung cancer cell lines is shown, respectively, according to one embodiment of the present invention.
[0045] Figure 7a Schematic diagram of MSLN-28-z, MSLN-4-1BB-z and MSLN-30S-z CAR structures according to one embodiment of the present invention is shown.
[0046] Figure 7b Shown is the expression level of human MSLN antigen (red area) in human lung cancer cell lines NCI-H292 and A549, human pancreatic cancer cell line AsPC-1, and human ovarian cancer cell line SKOV3 analyzed by flow cytometry based on isotype (grey area) according to one embodiment of the present invention.
[0047] Figure 7c The figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with MSLN-28-z, MSLN-4-1BB-z and MSLN-30S-z CARs analyzed by flow cytometry based on the group without CAR introduction (NT, blue area) according to one embodiment of the present invention.
[0048] Figure 7d The cytolytic activities of αβT and γδT cells introduced with MSLN-28-z, MSLN-4-1BB-z and MSLN-30S-z CARs at various E / T ratios against MSLN-positive and negative human cancer cell lines, respectively, are shown according to one embodiment of the present invention.
[0049] Figure 7e Schematic diagram of MSLN-28-BB-z, MSLN-30S-BB-z and MSLN-28-30S-z CAR structures according to one embodiment of the present invention is shown.
[0050] Figure 7f The figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with MSLN-28-BB-z, MSLN-30S-BB-z and MSLN-28-30S-z CARs, analyzed by flow cytometry, based on the group without CAR introduction (NT, blue area) according to one embodiment of the present invention.
[0051] Figure 7gThe cytolytic activities of αβT and γδT cells introduced with MSLN-28-BB-z, MSLN-30S-BB-z and MSLN-28-30S-z CARs at various E / T ratios against MSLN-positive and negative human cancer cell lines, respectively, are shown according to one embodiment of the present invention.
[0052] Figure 8a Schematic diagram of GPC3-28-BB-z, GPC3-30S-BB-z and GPC3-28-30S-z CAR structures according to one embodiment of the present invention is shown.
[0053] Figure 8b Shown is the expression level of human GPC3 antigen (red area) in human liver cancer cell line HepG2 and human lung cancer cell lines NCI-H292 and A549 analyzed by flow cytometry based on isotype (grey area) according to one embodiment of the present invention.
[0054] Figure 8c The figure shows the expression level of each CAR (red area) in γδT cells introduced with GPC3-28-BB-z, GPC3-30S-BB-z and GPC3-28-30S-zCARs, analyzed by flow cytometry, based on the group without CAR introduction (NT, blue area) according to one embodiment of the present invention.
[0055] Figure 8d The cytolytic activity of γδ T cells introduced with GPC3-28-BB-z, GPC3-30S-BB-z and GPC3-28-30S-z CARs at various E / T ratios against each of GPC3-positive and negative human cancer cell lines is shown according to one embodiment of the present invention.
[0056] Figure 9a Schematic diagrams of PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z and PD-1-28TM CAR structures according to one embodiment of the present invention are shown.
[0057] Figure 9b The expression levels of human PD-L1 antigen (red area) in human pancreatic cancer cell line AsPC-1, human lung cancer cell lines NCI-H292 and Calu-1, and human head and neck cancer cell line FaDu analyzed by flow cytometry based on isotype (grey area) according to one embodiment of the present invention are shown.
[0058] Fig.9cThe figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z and PD-1-28TM CAR based on the group without CAR introduction (NT, blue area) analyzed by flow cytometry according to one embodiment of the present invention.
[0059] Figure 9d The cytolytic activity of αβT and γδT cells introduced with PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z and PD-1-28TM CAR at various E / T ratios against each of PD-L1 positive and negative human cancer cell lines is shown, respectively, according to one embodiment of the present invention.
[0060] Fig.9e Schematic diagram of PD-1-28-BB-z, PD-1-30S-BB-z and PD-1-28-30S-z CAR structures according to one embodiment of the present invention is shown.
[0061] Figure 9f The figure shows the expression level of each CAR (red area) in γδT cells introduced with PD-1-28-BB-z, PD-1-30S-BB-z and PD-1-28-30S-zCAR based on the group without CAR introduction (NT, blue area) analyzed by flow cytometry according to one embodiment of the present invention.
[0062] Figure 9g The cytolytic activity of γδ T cells introduced with PD-1-28-BB-z, PD-1-30S-BB-z, and PD-1-28-30S-z CARs at various E / T ratios against each of PD-L1 positive and negative human cancer cell lines is shown according to one embodiment of the present invention.
[0063] Fig.10a A schematic diagram of the NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z CAR structures according to one embodiment of the present invention is shown.
[0064] Fig.10b Shown is the expression level of human B7-H6 antigen (red area) in human blood cancer cell lines U937, Raji and K562 and human lung cancer cell line A549 analyzed by flow cytometry based on isotype (grey area) according to one embodiment of the present invention.
[0065] Fig.10cThe figure shows the expression level of each CAR (red area) in αβT and γδT cells introduced with NKp30-28-BB-z, NKp30-30S-BB-z and NKp30-28-30S-z CARs, analyzed by flow cytometry, based on the group without the introduction of CAR (NT, blue area) according to one embodiment of the present invention.
[0066] Fig.10d The cytolytic activity of αβT and γδT cells introduced with NKp30-28-BB-z, NKp30-30S-BB-z and NKp30-28-30S-z CARs at various E / T ratios against each of B7-H6 positive and negative human cancer cell lines is shown, respectively.
[0067] Fig.11a and 11b The therapeutic anti-tumor results of second-generation CD19-CAR expressing T cells based on the combination of CD30S with existing ICD (CD28, 4-1BB) in an animal model of xenograft human leukemia cell line NALM6 are shown. Fig.11a shows tumor growth over time in CD19-28-z, CD19-4-1BB-z, and CD19-30S-z CAR-αβT cell treatment groups according to one embodiment of the present invention, Fig.11b Survival rates of mice in the control group and CD19-28-z, CD19-4-1BB-z, and CD19-30S-z CAR-αβT cell treatment groups up to 48 days are shown. Tumor growth was monitored by in vivo bioluminescence imaging of individual mice and quantified as the average amount of bioluminescence. DETAILED DESCRIPTION
[0068] Hereinafter, the features of the present invention will be described in detail.
[0069] The present invention relates to a chimeric antigen receptor, comprising: a target antigen binding domain; a transmembrane domain; a C30-derived intracellular signaling domain, which comprises one or more amino acid sequences selected from the group consisting of SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48 and SEQ ID NO: 50; and a CD3 zeta intracellular signaling domain.
[0070] The present invention is characterized in that it provides a chimeric antigen receptor comprising a partial sequence of a TNF receptor-associated factor (TRAF) binding site in a CD30 domain as an intracellular signal transduction domain.
[0071] CD30 is a 120kD transmembrane glycoprotein receptor, a member of the tumor necrosis factor receptor (TNFR) family and expressed in T cells and B cells. When activated, CD30 recruits TNFR-related factors (TRAF1, TRAF2, TRAF5) and activates JUNB or AP-1 transcription factors through NF-kB or MAPK signaling pathways. In this way, not only the proliferation and survival of T cells are improved, but also their phenotype is differentiated into a memory type. Therefore, in order to utilize the signals transmitted by TRAF to improve the proliferation and survival of immune effector cells, especially CAR-T cells, the inventors produced various types of CD30 domains (CD30L, CD30M, CD30M) for the TRAF binding sites (domains 1, 2, 3) of the CD30 domain. mut , CD30M, CD30S), and the results confirmed that when the 57a.a. region of 539-595a.a. or 544-588a.a. of domain 2+3 was used as the chimeric antigen receptor intracellular signaling domain, the anti-tumor efficacy and cytokine secretion capacity were improved.
[0072] As the intracellular signaling domain of the chimeric antigen receptor of the present invention, CD30ΔS further comprising specific amino acids YMNM or YMFM, i.e., 544-588a.a.+YMNM or YMFM, is used in addition to the 539-595a.a. or 544-588a.a. region of domain 2+3. These amino acid sequences are sequences not present in wild-type CD30 and are phosphoinositide 3-kinase binding site sequences, and according to one embodiment, the anti-tumor efficacy and cytokine secretion capacity of immune effector cells are similar to those when only 539-595a.a. or 544-588a.a. of domain 2+3 of CD30 is used for the chimeric antigen receptor.
[0073] Therefore, the chimeric antigen receptor of the present invention is characterized in that it significantly improves the anti-tumor efficacy and cytokine secretion ability of immune effector cells by using the intracellular signaling domain comprising the 539-595a.a. region or the 544-588a.a. region or the 544-588a.a.+YMNM or YMFM sequence of domain 2+3 of CD30S.
[0074] The term "chimeric antigen receptor (CAR)" used in the present invention generally refers to a fusion protein comprising an extracellular domain capable of binding to an antigen and one or more intracellular domains. CAR may include an antigen (e.g., surface antigen, tumor-associated antigen, etc.) binding domain, a transmembrane domain, and an intracellular signaling domain. Based on target antigen specificity, CAR can be combined with a T cell receptor activation intracellular domain. Genetically modified T cells expressing CAR can specifically recognize and eliminate malignant cells expressing target antigens.
[0075] The term "target antigen binding domain" used in the present invention generally refers to a domain that has the ability to specifically bind to an antigen protein. For example, it can be an antibody or a fragment thereof that specifically binds to a target antigen.
[0076] The term "binding domain" used in the present invention can be used interchangeably with "extracellular domain", "extracellular binding domain", "antigen-specific binding domain" and "extracellular antigen-specific binding domain", and refers to a CAR domain or fragment that has the ability to specifically bind to a target antigen.
[0077] The target antigen can be a surface antigen or a tumor-associated antigen expressed in a blood cancer or a solid cancer. For example, the antigen can be selected from CD19, MUC16, MUC1, CAIX, CEA, CDS, CD7, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, BCMA, PD-1, NKp30, cytomegalovirus (CMV) infected cell antigen, EGP-2, EGP-40, EpCAM, Erb-B2, Erb-B3, Erb-B4, FBP, fetal acetylcholine receptor, folate receptor-α, GD2, GD3, HER-2, hTERT, IL-13R-α2, κ-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, NKG2D ligand, NY-ESO-1, carcinoembryonic antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, CD24, CD47, EGFR, CD123, GPC3, CD117, Claudin18.2, cMET, EphA2, CLL-1, CD171, AXL, ROR2, FAP or CD5, but are not limited thereto.
[0078] In the present invention, the antibody that specifically binds to the target antigen can be a monoclonal antibody. The term "monoclonal antibody" used in the present invention is an antibody produced by a single antibody-forming cell, and is characterized by a consistent primary structure (amino acid sequence). Monoclonal antibodies only recognize one antigenic determinant, and are generally produced by culturing hybridoma cells fused with cancer cells and antibody-producing cells, but other host cells expressing recombinant proteins can also be used to produce them using fixed antibody gene sequences.
[0079] The term "antibody" used in the present invention can be used not only in its complete form having two full-length light chains and two full-length heavy chains, but also in the form of a fragment of an antibody molecule. A fragment of an antibody molecule refers to a fragment having at least one peptide tag (epitope) binding function, including scFv, Fab, F(ab'), F(ab')2, a single domain, etc.
[0080] Among antibody fragments, Fab is a structure having variable regions of light and heavy chains, constant regions of light chains and the first constant region (CH1) of heavy chains, and it has one antigen binding site. Fab' is different from Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the heavy chain CH1 domain. When the cysteine residues in the hinge region of Fab' form a disulfide bond, a F(ab')2 antibody is produced. Fv is the smallest antibody fragment having only heavy chain variable regions and light chain variable regions. Recombinant techniques for producing Fv fragments are disclosed in international patents WO 88 / 10649, WO 88 / 106630, WO 88 / 07085, WO 88 / 07086 and WO 88 / 09344. In disulfide-stabilized Fv (dsFv), the heavy chain variable region and the light chain variable region are linked by disulfide bonds, while in single-chain Fv (scFv), the heavy chain variable region and the light chain variable region are usually covalently linked by a peptide linker. These antibody fragments can be obtained using proteolytic enzymes (e.g., Fab can be obtained by restricted digestion of whole antibodies with papain, and F(ab')2 fragments can be obtained by digestion with pepsin). Preferably, they can be produced by genetic recombination technology.
[0081] The term "humanized antibody" as used herein is an antibody having an amino acid sequence corresponding to an antibody produced by a human and / or produced using one of the techniques disclosed herein for producing human antibodies. This definition of a humanized antibody explicitly excludes a humanized antibody that comprises a non-human antigen-binding portion.
[0082] In addition, the proteins, polypeptides and / or amino acid sequences included in the present invention should be understood to include at least functional variants or homologs having the same or similar functions as the proteins or polypeptides.
[0083] In the present invention, functional variants can be proteins or polypeptides obtained by replacing, lacking or adding one or more amino acids in the amino acid sequence of proteins and / or polypeptides. For example, functional variants can include proteins or polypeptides having different amino acid sequences due to replacement, lack and / or insertion of one or more amino acids, such as 1 to 30, 1 to 20 or 1 to 10 or 1, 2, 3, 4 or 5 amino acids. Functional variants can substantially maintain the biological properties of unmodified proteins or polypeptides (replacement, lack or addition). For example, functional variants can retain at least 60%, 70%, 80%, 90% or 100% of the biological activity (e.g., antigen binding ability) of the original protein or polypeptide.
[0084] In the present invention, a homolog may be a protein or polypeptide (e.g., an antibody that can specifically bind to BCMA or a fragment thereof) having about 85% or more amino acid sequence homology (e.g., about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) with the protein and / or polypeptide.
[0085] In the present invention, homology generally refers to the similarity or relatedness between two or more sequences.
[0086] The term "transmembrane domain" used in the present invention generally refers to a CAR domain that plays a signaling role by passing through the cell membrane and connecting to the intracellular signaling domain. The transmembrane domain is connected between the C-terminus of the target antigen binding domain and the N-terminus of the intracellular signaling domain, and can be a transmembrane domain of a TCR co-receptor or T cell co-stimulatory molecule selected from the group consisting of: CD8, 4-1BB, CD27, CD28, CD30, OX40, CD3e, CD3ζ, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154 and ICOS (CD278), or can be derived therefrom. In particular, the transmembrane domain of CD28 can be used.
[0087] The hinge region can be connected between the C-terminus of the target antigen binding domain and the N-terminus of the transmembrane domain, and as the hinge region, a hinge region derived from CD8α or CD28 can be used. "Hinge region" generally refers to the connecting region between the antigen binding region and the immune cell Fc receptor (FcR) binding region.
[0088] The term "intracellular signaling domain" (or intracellular signal transduction domain) used in the present invention refers to a domain that is generally located inside a cell and is capable of transmitting a signal. In the present invention, not only 539-595a.a. of domain 2+3 in the TRAF binding site of the CD30 region or its deletion site 544-588a.a. can be used as an intracellular signaling domain, but also CD30S containing specific amino acids YMNM or YMFM in addition to 544-588a.a. can be used as an intracellular signaling domain. More specifically, the amino acid sequence of SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48 or SEQ ID NO: 50 can be included.
[0089] As the CAR of the present invention, a third-generation chimeric antigen receptor can be used, which further comprises an intracellular signaling domain selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40 and KIR2DS2.
[0090] The CD3ζ intracellular signaling domain of the CAR of the present invention may have an amino acid sequence of SEQ ID NO: 18, which corresponds to nucleotides 154-492 derived from CD3ζ (NCBI NM_198053.2), but is not limited thereto.
[0091] In addition, the CAR of the present invention may also include a signal peptide at the N-terminus of the target antigen binding domain, and "signal peptide" generally refers to a peptide chain for guiding protein delivery. As a signal peptide, a granulocyte macrophage colony stimulating factor (GM-CSF) receptor signal sequence, a CD8α signal sequence, an immunoglobulin heavy chain signal sequence, a PD-1 signal sequence, and a NKp30 signal sequence can be used, but are not limited thereto.
[0092] According to one embodiment of the present invention, the CAR of the present invention may be a second-generation CAR, in which the following are connected in sequence: a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; a CD30-derived intracellular signaling domain; and a CD3ζ intracellular signaling domain.
[0093] According to another embodiment of the present invention, the CAR of the present invention can be a third-generation CAR, in which the following are connected in sequence: a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; a CD30-derived intracellular signaling domain; an intracellular signaling domain (co-stimulatory domain) selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD40, ICOS, LFA-1, CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40 and KIR2DS2; and a CD3ζ intracellular signaling domain.
[0094] The present invention also relates to nucleic acid molecules encoding CAR.
[0095] The nucleic acid molecule encoding CAR may comprise polynucleotides encoding the following, respectively: a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; a CD30-derived intracellular signaling domain; and a CD3ζ intracellular signaling domain.
[0096] The nucleic acid molecule encoding CAR may include polynucleotides encoding the following, respectively: a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; a CD30-derived intracellular signaling domain; an intracellular signaling domain (co-stimulatory domain) selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD40, ICOS, LFA-1, CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40 and KIR2DS2; and a CD3ζ intracellular signaling domain
[0097] More specifically, the CD30-derived intracellular signaling domain may comprise the base sequence of SEQ ID NO:47 or SEQ ID NO:49.
[0098] In the present invention, the term "polynucleotide" generally refers to an isolated nucleic acid molecule, deoxyribonucleotide or ribonucleotide or its analogue of any length. For example, the polynucleotide of the present invention can be produced by: (1) in vitro amplification, such as polymerase chain reaction (PCR) amplification; (2) cloning and recombination; (3) purification, such as digestion and gel electrophoresis separation; (4) synthesis, such as chemical synthesis, and preferably, the isolated polynucleotide is produced by recombinant DNA technology. In the present invention, nucleic acids encoding antibodies or antigen-binding fragments thereof can be produced by a variety of methods known in the art, including restriction fragment manipulation of synthetic oligonucleotides or splicing by overlap extension (SOE) PCR, but are not limited thereto.
[0099] The present invention also relates to a vector comprising a nucleic acid molecule encoding a CAR.
[0100] The term "expression vector" used in the present invention refers to a gene product containing necessary regulatory elements (e.g., promoters) to enable the target gene to be expressed in a suitable host cell. The vector may be selected from one or more of a plasmid, a retroviral vector, and a lentiviral vector. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or in some cases may be integrated into the genome itself.
[0101] In addition, the vector may include expression control elements that allow the coding region to be correctly expressed in a suitable host. These control elements are well known to those skilled in the art, and may include, for example, promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation. The specific structure of the expression control sequence may vary due to the function of the species or cell type, but generally includes 5' non-transcribed sequences and 5' or 3' non-translated sequences that participate in transcription initiation and translation initiation, such as TATA boxes, capping sequences, CAAT sequences, etc. For example, the 5' non-transcribed expression control sequence may include a promoter region, and the promoter region may include a promoter sequence for transcribing a functionally connected nucleic acid and regulating its transcription.
[0102] The promoter is operably connected to induce the expression of the target antigen binding domain, wherein "operably connected" refers to the functional connection of the nucleic acid expression regulatory sequence with the nucleic acid sequence encoding the target protein to exert a general function. Gene recombination techniques known in the art can be used to produce an operable connection with a recombinant vector, and enzymes known in the art can be used to achieve site-specific DNA cutting and connection.
[0103] Methods for introducing genes into cells and expressing them in cells are known in the art. Regarding expression vectors, vectors can be easily introduced into host cells by any method in the art. For example, expression vectors can be introduced into host cells by physical, chemical or biological methods.
[0104] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection and electroporation. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, Vol. 1-4, Cold Spring Harbor Press, NY.
[0105] Biological methods for introducing polynucleotides into host cells include the use of DNA and RNA vectors. Viral vectors, especially retroviral vectors, have become the most widely used methods for inserting genes into mammalian cells (e.g., human cells). Other viral vectors may come from lentiviruses, poxviruses, herpes simplex viruses, adenoviruses, adeno-associated viruses, etc.
[0106] Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres and beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle). Other methods are available for the targeted delivery of nucleic acids in the prior art, such as using targeted nanoparticles or other suitable submicron-level delivery systems to deliver polynucleotides.
[0107] When using a non-viral delivery system, an exemplary delivery vehicle is a liposome. Consider using lipid formulations to introduce nucleic acid into a host cell (in vitro, in vitro or in vivo). In another aspect, nucleic acid can be combined with lipids. Nucleic acids combined with lipids can be encapsulated in the aqueous interior of liposomes, dispersed in the lipid bilayer of liposomes, attached to liposomes by connecting molecules combined with liposomes and oligonucleotides, captured in liposomes, compounded with liposomes, dispersed in lipid-containing solutions, mixed with lipids, combined with lipids, included in lipids as a suspension, included in micelles or compounded with micelles, or otherwise combined with lipids. Lipid, lipid / DNA or lipid / expression vector binding compositions are not limited to any specific structure in the solution.
[0108] The present invention also relates to an immune effector cell, which comprises a CAR, a nucleic acid molecule encoding the CAR, or a vector comprising the nucleic acid molecule.
[0109] The immune effector cells may be cells of mammalian origin, preferably αβT cells, γδT cells, NK cells (including KHYG-1 and NK-92 cell lines), NK T cells or macrophages.
[0110] CAR-expressing immune effector cells can be generated by introducing the CAR vector of the present invention into immune effector cells such as T cells or NK cells.
[0111] Specifically, CAR vectors can be introduced into cells by methods known in the art, such as electroporation and cationic liposomes (Lipofectamine) (Lipofectamine 2000, Invitrogen Corporation). For example, plasmids can be introduced into immune effector cells by electroporation to ensure long-term stable CAR expression.
[0112] The immune effector cells for producing immune effector cells expressing CAR can be obtained from an object, wherein "object" includes a living organism (e.g., a mammal) to which an immune response can be induced. The example of an object includes people, dogs, cats, mice, rats and their transformants. T cells can be obtained from many sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue at the site of infection, ascites, pleural effusion, spleen tissue and tumor.
[0113] Any of a variety of techniques known to those skilled in the art may be used (e.g. T cells are obtained by separation (isolation) from a blood unit collected from a subject. The cells in the blood are obtained by apheresis, and the apheresis product generally contains lymphocytes, including T cells, monocytes, granulocytes and B cells, other nucleated white blood cells, red blood cells and platelets.
[0114] Cells collected by apheresis can be washed to remove the plasma fraction and placed in an appropriate buffer or medium for subsequent processing steps. T cells are separated from peripheral blood lymphocytes by gradient centrifugation or counterflow centrifugation.
[0115] The present invention also relates to an anti-tumor composition comprising the above immune effector cells.
[0116] According to one embodiment of the present invention, the immune effector cells introduced into the CAR containing the CD30-derived intracellular signaling domain exhibit specific cytolytic ability for CD19-positive blood cancer cell lines, BCMA-positive cell lines, EpCAM solid tumor cell lines, mesothelin-positive solid cancer cell lines, GPC3-positive solid cancer cell lines, PD-L1-positive solid cancer cell lines, B7-H6-positive cell lines, etc. Therefore, the immune effector cells introduced into the CAR of the present invention can be used to treat blood cancer or solid cancer.
[0117] Solid cancer can be lung cancer, colorectal cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, melanoma, retinoblastoma, thymus cancer, stomach cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer or pancreatic cancer. In addition, blood cancer can be lymphoma, leukemia or multiple myeloma.
[0118] The pharmaceutical composition may also contain a pharmaceutically acceptable carrier. For oral administration, binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, colorants, flavoring agents, etc. may be used; and in the case of injection, buffers, preservatives, analgesics, solubilizers and isotonic agents, stabilizers, etc. may be mixed and used; and in the case of external administration, bases, excipients, lubricants, preservatives, etc. may be used.
[0119] The dosage form of the pharmaceutical composition can be prepared into various forms by mixing with the above-mentioned pharmaceutically acceptable carriers. For example, for oral administration, the pharmaceutical composition can be prepared into tablets, lozenges, capsules, elixirs, suspensions, syrups, thin tablets and the like, and in the case of injection, can be prepared into unit dose ampoules or multiple dose forms.
[0120] In addition, the pharmaceutical composition may also include a surfactant that can improve membrane permeability. The surfactant may be derived from a steroid, or may be a cationic lipid such as N-[1-(2,3-dioleoyl)propyl-N,N,N-trimethylammonium chloride (DOTMA), or various compounds such as cholesterol hemisuccinate and phosphatidylglycerol, but is not limited thereto.
[0121] The pharmaceutical composition can be administered together or sequentially with the above-mentioned pharmacological or physiological components, and can also be administered in combination with additional conventional therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. Such administration can be a single administration or multiple administrations. Taking into account all of the above factors, it is important that the administration can achieve the maximum effect with the minimum amount without side effects, and can be easily determined by those skilled in the art.
[0122] The term "administer" used in the present invention refers to providing the pharmaceutical composition of the present invention to a subject by any suitable method. The pharmaceutical composition of the present invention can be administered in the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, an animal or a human as considered by a researcher, veterinarian, physician or other clinician, i.e., a therapeutically effective amount that induces symptom relief of a disease or disorder being treated. It is obvious to those skilled in the art that the therapeutically effective dose and the number of administrations of the pharmaceutical composition of the present invention will vary according to the desired effect. Therefore, the optimal administration dose can be easily determined by those skilled in the art, and can be adjusted according to a variety of factors, including the type of disease, the severity of the disease, the content of the active ingredient and other ingredients contained in the composition, the type of dosage form, the age, weight, general health, sex and diet of the patient, the time of administration, the route of administration, the secretion rate of the composition, the treatment period and the drugs used simultaneously. The pharmaceutical composition of the present invention can be administered in an amount of 1 to 10,000 mg / kg / day, and can be administered once a day or in multiple divided doses.
[0123] The term "subject" used in the present specification refers to a mammal suffering from or at risk of suffering from a condition or disease that can be alleviated, suppressed or treated by administering a pharmaceutical composition, and preferably, it refers to a human.
[0124] Therefore, the present invention also provides a method for treating cancer, comprising administering a therapeutically effective amount of immune effector cells to a subject in need thereof.
[0125] Immune effector cells can be administered in a pharmaceutically effective amount to treat cancers expressing tumor antigens. The pharmaceutically effective amount may vary depending on a variety of factors, including the type of disease, the age and weight of the patient, the nature and severity of the symptoms, the type of current treatment, the number of treatments, and the form and route of administration, and can be readily determined by an expert in the art.
[0126] The subject is the same as the subject to which the pharmaceutical composition of the present invention is administered.
[0127] The present invention will be described in more detail below through examples according to the present invention, but the scope of the present invention is not limited to the examples given below. Example <Example 1> Production of CAR (human cell line)
[0128] Human multiple myeloma cell line IM-9 and human lymphoma cell line U937 mock and U937 CD19 , human Burkitt's lymphoma cell line Raji, human lung cancer cell lines NCI-H292 and NCI-H460, and human pancreatic cancer cell line AsPC-1 were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS). Human liver cancer cell line HepG2, human lung cancer cell lines A549 and Calu-1, and human head and neck cancer cell line FaDu were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco) containing 10% FBS. Human ovarian cancer cell line SKOV3 was maintained in McCoy's medium (Gibco) containing 10% FBS. Natural killer cell lines KHYG-1 and NK-92 were maintained in RPMI-1640 containing 10% FBS and 300 U / ml interleukin-2 (IL-2). αβ T cells were maintained in RPMI-1640 containing 10% FBS and 500 U / ml IL-2. γδ T cells were cultured in RPMI-1640 containing 10% FBS and 1000 U / ml IL-2. (Human αβT and γδT cell culture)
[0129] For αβT cell culture, peripheral blood mononuclear cells (PBMCs) were placed in culture dishes attached with anti-CD3 antibodies (2 μg / ml) and anti-CD28 antibodies (2 μg / ml) and containing RPMI-1640 (10% FBS) containing 300 U / ml IL-2, and cultured in a cell culture incubator at 37°C for seven days. Subculture was performed by replacing the culture medium with fresh culture medium every two or three days. On day 7, the number of αβT cells was measured and the cells were frozen in a freezing solution consisting of 10% dimethyl sulfoxide (DMSO) and 90% FBS.
[0130] For γδT cell culture, PBMCs were cultured in a culture medium containing 5 μM zoledronic acid and 500 U / ml IL-2 in a cell culture incubator at 37 ° C for 7 days. Subculture was performed by replacing the culture medium with fresh culture medium every two or three days. After counting the number of γδT cells on day 7, feeder cells irradiated with X-rays at an intensity of 120 Gy were cultured together at a ratio of γδT cells: feeder cells of 2:1 for 7 days. The number of γδT cells cultured for 14 days was measured, and the cells were frozen using the same freezing solution as above. (Plasmid) –CD19 scFv
[0131] The GM-CSF receptor signal sequence, the variable light chain (VL) and heavy chain (VH) regions of the FMC63 anti-CD19 antibody, the hinge and transmembrane domains of CD28; the hinge and transmembrane domains of CD8α; the hinge and transmembrane domains of CD28; the intracellular signaling domain; and the intracellular signaling domains of CD28, CD30 and various mutants of CD30, 4-1BB, CD27, ICOS, OX40 and CD3ζ (CD3z) were artificially synthesized. These domains were assembled into various combinations using PCR (PCR overlap extension). The PCR products amplified by connecting XhoI, EcoRV and NotI sequences to both ends were inserted (fusion cloned, connected) into the XhoI and NotI sites of the pCI vector (pCI mammalian expression vector, Promega E1731). The PCR products were confirmed by sequencing. -BCMA
[0132] The GM-CSF receptor signal sequence, the VL and VH regions of the Bb2121 anti-BCMA antibody, and the hinge and transmembrane domains of CD28 were artificially synthesized; the intracellular signaling domain; and the intracellular signaling domains of CD28, 4-1BB, CD30 mutants, and CD3ζ (CD3z). Like the CD19 scFv, these domains were assembled using PCR and inserted into the pCI vector, and the PCR products were confirmed by sequencing. -EpCAM
[0133] The scFv signal sequence (CD8α signal sequence), the VL and VH regions of the VB4-845 anti-EpCAM antibody, and the hinge and transmembrane domains of CD8α were artificially synthesized; the hinge and transmembrane domains of CD28; the intracellular signaling domain; and the intracellular signaling domains of CD28, 4-1BB, CD30 mutants, and CD3ζ (CD3z). As with the CD19 scFv, these domains were assembled using PCR and inserted into the pCI vector, and the PCR products were confirmed by sequencing. -Mesothelin
[0134] The scFv signal sequence (GM-CSF receptor signal sequence), the VL and VH regions of the MORAb-009 anti-mesothelin antibody, and the hinge and transmembrane domains of CD8α were artificially synthesized; the hinge and transmembrane domains of CD28; the intracellular signaling domain; and the intracellular signaling domains of CD28, 4-1BB, CD30 mutants, and CD3ζ (CD3z). As with the CD19 scFv, these domains were assembled using PCR and inserted into the pCI vector, and the PCR products were confirmed by sequencing. -Glypican-3
[0135] The immunoglobulin heavy chain signal sequence, the VL and VH regions of the GC33 anti-phosphatidylinositol glycan-3 antibody, and the hinge and transmembrane domains of CD28 were artificially synthesized; the intracellular signaling domain; and the intracellular signaling domains of CD28, 4-1BB, CD30 mutants, and CD3ζ (CD3z). Like the CD19 scFv, these domains were assembled using PCR and inserted into the pCI vector, and the PCR products were confirmed by sequencing. -PD-1ECD
[0136] The signal sequence and extracellular domain of PD-1, the hinge and transmembrane domain of CD28, the intracellular signaling domain, and the intracellular signaling domain of CD28, 4-1BB, CD30 mutants, and CD3ζ (CD3z) were artificially synthesized. As with CD19scFv, these domains were assembled using PCR and inserted into the pCI vector, and the PCR products were confirmed by sequencing. -NKp30
[0137] The signal sequence and extracellular domain of NKp30, the hinge and transmembrane domain of CD28, the intracellular signaling domain, and the intracellular signaling domains of CD28, 4-1BB, CD30 mutants and CD3ζ (CD3z) were artificially synthesized respectively.
[0138] As with the CD19 scFv, these domains were assembled using PCR and inserted into the pCI vector, and the PCR products were confirmed by sequencing.
[0139] The above CARs are listed in Tables 1 to 13, and their sequences are listed in Table 14. All CAR domains are linked to each other in tandem and in frame. [Table 1] Second-generation CAR targeting CD19: CD30 domain screening
[0140] The CD19-28-z shown in Table 1 comprises the signal sequence domain of the human GM-CSF receptor (1-66 nucleotides (nt), NCBI reference sequence ID: 001161531.2); the VL and VH regions of the FMC63 anti-CD19 antibody (KR10-2019-7034220 / WO2018 / 200496JS scFv); hinge (340-456nt, NCBI reference sequence: NM_006139.2) and transmembrane domain (457-537nt, NCBI reference sequence: NM_006139.2) derived from human CD28; intracellular signaling domain derived from human CD28 (538-660nt, NCBI reference sequence: NM_006139.2); and intracellular signaling domain derived from human CD3z (154-492nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2) linked to the stop codon TAA.
[0141] CD19-30L-z is identical to CD19-28-z except that a human CD8α-derived hinge (412-546 nt, NCBI Reference Sequence: NM_001768) and a human CD30-derived intracellular signaling domain (1219-1785 nt, NCBI Reference Sequence: NM_001243.3) are used.
[0142] CD19-30M-z is identical to CD19-28-z except that a human CD8α-derived hinge (412-546 nt, NCBI Reference Sequence: NM_001768) and a truncation mutant of the human CD30-derived intracellular signaling domain (1501-1785 nt, NCBI Reference Sequence: NM_001243.3) are used.
[0143] CD19-30M Mut-z is identical to CD19-28-z except that a human CD8α-derived hinge (412-546 nt, NCBI reference sequence: NM_001768) and a truncation mutant of the human CD30-derived intracellular signaling domain (1501-1785 nt of amino acids 521, K→Q, NCBI reference sequence: NM_001243.3) are used.
[0144] CD19-30ΔM-z is identical to CD19-28-z except that a human CD8α-derived hinge (412-546 nt, NCBI reference sequence: NM_001768) and truncation mutants of the human CD30-derived intracellular signaling domain (1501-1614 and 1678-1785 nt, NCBI reference sequence: NM_001243.3) were used.
[0145] CD19-30S-z is identical to CD19-28-z except that a human CD8α-derived hinge (412-546 nt, NCBI Reference Sequence: NM_001768) and a truncation mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) are used. [Table 2] Second-generation CAR targeting CD19: modified form of CD30S
[0146] The CD19-30S-z shown in Table 2 comprises the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI reference sequence ID: 001161531.2); the VL and VH regions of the FMC63 anti-CD19 antibody (KR10-2019-7034220 / WO2018 / 200496JS scFv); hinge (340-456 nt, NCBI reference sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI reference sequence: NM_006139.2) derived from human CD28; truncation mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI reference sequence: NM_001243.3); and the intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2, codon optimized) linked to the stop codon TAA.
[0147] CD19-30ΔS-z is the same as CD19-30S-z in Table 2, except that a truncation mutant of the human CD30-derived intracellular signaling domain (1630-1764 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain.
[0148] CD19-30ΔS YN -z is the same as CD19-30S-z in Table 2, except that a domain formed by combining a truncation mutant of the human CD30-derived intracellular signaling domain (1630-1764 nt of CD30) with the YMNM (16 a.a.) region (which is a part of the CD28 intracellular signaling domain) is used as the first signaling domain.
[0149] CD19-30ΔS YF -z is the same as CD19-30S-z in Table 2, except that a domain formed by combining a truncation mutant of the human CD30-derived intracellular signaling domain (1630-1764 nt of CD30) with the YMFM (16 a.a.) region (which is a part of the CD28 intracellular signaling domain) is used as the first signaling domain. [Table 3] Second-generation CAR targeting CD19
[0150] CD19-28-z and CD19-30S-z were produced in the same manner as described above. CD19-4-1BB-z is the same as CD19-30S-z, except that an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the first intracellular signaling domain.
[0151] CD19-27-z is identical to CD19-30S-z, except that a human CD27-derived intracellular signaling domain (640-780 nt, NCBI reference sequence: NM_001242.4) is used as the first intracellular signaling domain.
[0152] CD19-ICOS-z is identical to CD19-30S-z, except that the human ICOS-derived intracellular signaling domain (484-597 nt, NCBI reference sequence: NM_012092.2) is used as the first intracellular signaling domain.
[0153] CD19-OX40-z is identical to CD19-30S-z except that a human OX40-derived intracellular signaling domain (706-831 nt, NCBI Reference Sequence: NM_003327.2) is used as the first intracellular signaling domain. [Table 4] The third generation CAR targeting CD19
[0154] CD19-28-BB-z contains the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI reference sequence ID: 001161531.2); the VL and VH regions of the FMC63 anti-CD19 antibody (KR10-2019-7034220 / WO2018 / 200496JSscFv); the hinge (340-456 nt, NCBI reference sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI reference sequence: NM_006139.3) derived from human CD28. .2); human CD28-derived intracellular signaling domain (538-660 nt, NCBI reference sequence: NM_006139.2); and human CD137 (4-1BB)-derived intracellular signaling domain (640-765 nt, NCBI reference sequence: NM_001561.4, codon-optimized); and human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2, codon-optimized) linked to the stop codon TAA.
[0155] CD19-30S-BB-z is identical to CD19-28-BB-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain, and the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the co-stimulatory domain (second signaling domain).
[0156] CD19-28-30S-z is identical to CD19-28-BB-z, except that a human CD28-derived hinge (340-456 nt, NCBI reference sequence: NM_006139.2) is used as the first signaling domain, and a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the co-stimulatory domain (second signaling domain).
[0157] CD19-30S-ICOS-z is identical to CD19-28-BB-z, except that a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) is used as the first signaling domain, and the human ICOS-derived intracellular signaling domain (484-597 nt, NCBI Reference Sequence: NM_012092.2) is used as the co-stimulatory domain (second signaling domain).
[0158] CD19-30S-CD27-z is identical to CD19-28-BB-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) is used as the first signaling domain, and the intracellular signaling domain derived from human CD27 (640-780 nt, NCBI Reference Sequence: NM_001242.4) is used as the co-stimulatory domain (second signaling domain).
[0159] CD19-30S-OX40-z is identical to CD19-28-BB-z, except that a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) is used as the first signaling domain, and the human OX40-derived intracellular signaling domain (706-831 nt, NCBI Reference Sequence: NM_003327.2) is used as the co-stimulatory domain (second signaling domain). [Table 5] The third generation CAR targeting BCMA
[0160] BCMA-28-30S-z contains the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI reference sequence ID: 001161531.2); the VL and VH regions of the Bb2121 anti-BCMA antibody (KR10-2021-7003369 / WO2020 / 014333); the transmembrane domain derived from human CD28 (457-537 nt, NCBI reference sequence: NM_006139.2); intracellular signaling domain (538-660 nt, NCBI reference sequence: NM_006139.2); a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI reference sequence: NM_001243.3); and a human CD3z-derived intracellular signaling domain linked to the stop codon TAA (154-492 nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2).
[0161] BCMA-28-BB-z is identical to BCMA-28-30S-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain (costimulatory domain).
[0162] BCMA-30S-BB-z is identical to BCMA-28-30S-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) is used as the first signaling domain, and the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) is used as the second signaling domain (costimulatory domain). [Table 6] Second-generation CAR targeting EpCAM abbreviation signal sequence scFv Connectors Hinge TM Signal-1 Signal-2 EpCAM-28-z CD8α VB4-845 (G4S)3 CD28 CD28 CD28 CD3ζ EpCAM-BB-z CD8α VB4-845 (G4S)3 CD28 CD28 4-1BB CD3ζ EpCAM-30S-z CD8α VB4-845 (G4S)3 CD28 CD28 CD30S CD3ζ EpCAM-28TM CD8α VB4-845 (G4S)3 CD28 CD28 - -
[0163] EpCAM-28-z contains the signal sequence domain of human CD8α (1-63 nt, NCBI reference sequence ID: NM_001768.5); the VL region of the optimized VB4-845 anti-EpCAM antibody (PCT / CA2008 / 001680); and the VH region (PCT / CA2008 / 001680); the hinge derived from human CD28 (340-456 nt, NCBI reference sequence: NM_006139. 2) and a transmembrane domain (457-537nt, NCBI reference sequence: NM_006139.2); a human CD28-derived intracellular signaling domain (538-660nt, NCBI reference sequence: NM_006139.2); and a human CD3z-derived intracellular signaling domain (154-492nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2) linked to the stop codon TAA.
[0164] EpCAM-BB-z is identical to EpCAM-28-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the first signaling domain.
[0165] EpCAM-30S-z is identical to EpCAM-28-z except that a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain.
[0166] EpCAM-28TM is identical to EpCAM-28-z except that it does not comprise the first signaling domain or the second signaling domain. [Table 7] The third generation CAR targeting EpCAM abbreviation signal sequence scFv Connectors Hinge TM Signal-1 Signal-2 Signal-3 EpCAM-28-30S-z CD8α VB4-845 (G4S)3 CD28 CD28 CD28 CD30S CD3ζ EpCAM-28-BB-z CD8α VB4-845 (G4S)3 CD28 CD28 CD28 4-1BB CD3ζ EpCAM-30S-BB-z CD8α VB4-845 (G4S)3 CD28 CD28 CD30S 4-1BB CD3ζ
[0167] EpCAM-28-30S-z contains the signal sequence domain of human CD8α (1-63 nt, NCBI reference sequence ID: NM_001768.5); the VL region (PCT / CA2008 / 001680); and the VH region (PCT / CA2008 / 001680) of the optimized VB4-845 anti-EpCAM antibody; the hinge (340-456 nt, NCBI reference sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI reference sequence :NM_006139.2); human CD28-derived intracellular signaling domain (538-660nt, NCBI reference sequence: NM_006139.2); a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785nt, NCBI reference sequence: NM_001243.3); and a human CD3z-derived intracellular signaling domain linked to the stop codon TAA (154-492nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2).
[0168] EpCAM-28-BB-z is identical to EpCAM-28-30S-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain (costimulatory domain).
[0169] EpCAM-30S-BB-z is identical to EpCAM-28-30S-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain, and the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain (costimulatory domain). [Table 8] Second-generation CAR targeting MSLN
[0170] MSLN(MOR)-28-z contains the signal sequence domain of human GM-CSF receptor (1-66 nt, NCBI Reference Sequence ID: 001161531.2); the VH region (atuximab, chimeric monoclonal antibody; γ1 heavy chain, 1-119) and VL region (atuximab, chimeric monoclonal antibody; κ light chain 1-106) of MORAb-009 anti-mesothelin antibody; the hinge derived from human CD28 (340-456 nt, NCBI Reference Sequence ID: NM _006139.2) and a transmembrane domain (457-537 nt, NCBI reference sequence: NM_006139.2); a human CD28-derived intracellular signaling domain (538-660 nt, NCBI reference sequence: NM_006139.2); and a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2) linked to the stop codon TAA.
[0171] MSLN(MOR)-BB-z is identical to MSLN(MOR)-28-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the first signaling domain.
[0172] MSLN(MOR)-30S-z is identical to MSLN(MOR)-28-z, except that a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) is used as the first signaling domain. [Table 9] The third generation CAR targeting MSLN
[0173] MSLN (MOR) -28-30S-z contains the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI Reference Sequence ID: 001161531.2); the VH region (atuximab, chimeric monoclonal antibody; γ1 heavy chain, 1-119) and VL region (atuximab, chimeric monoclonal antibody; κ light chain 1-106) of the MORAb-009 anti-mesothelin antibody; the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence ID: I reference sequence: NM_006139.2); human CD28-derived intracellular signaling domain (538-660 nt, NCBI reference sequence: NM_006139.2); a truncation mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI reference sequence: NM_001243.3); and a human CD3z-derived intracellular signaling domain linked to the stop codon TAA (154-492 nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2, codon optimized).
[0174] MSLN(MOR)-28-BB-z is identical to MSLN(MOR)-28-30S-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain.
[0175] MSLN(MOR)-30S-BB-z is identical to MSLN(MOR)-28-30S-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain and the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain. [Table 10] The third generation CAR targeting GPC3
[0176] GPC3-28-30S-z contains the signal sequence domain of human immunoglobulin heavy chain (1-57 nt, GenBank ID: AAC18316.1); the VL and VH regions of GC33 anti-GPC3 antibody (US2017 / 0281683); the transmembrane domain derived from human CD28 (457-537 nt, NCBI reference sequence: NM_006139.2); the intracellular signaling domain derived from human CD28 (5 38-660nt, NCBI reference sequence: NM_006139.2); a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785nt, NCBI reference sequence: NM_001243.3); and a human CD3z-derived intracellular signaling domain linked to the stop codon TAA (154-492nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2).
[0177] GPC3-28-BB-z is identical to GPC3-28-30S-z, except that a human CD137 (4-1BB)-derived intracellular signaling domain (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain.
[0178] GPC3-30S-BB-z is identical to GPC3-28-30S-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain, and the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain. [Table 11] Second-generation CAR targeting PD-L1 abbreviation signal sequence ECD TM Signal-1 Signal-2 PD-1-28-z PD-1 PD-1 PD-1 5aa+CD28 CD28 CD3ζ PD-1-BB-z PD-1 PD-1 PD-1 5aa+CD28 4-1BB CD3ζ PD-1-30S-z PD-1 PD-1 PD-1 5aa+CD28 CD30S CD3ζ PD-1-28TM PD-1 PD-1 PD-1 5aa+CD28 - -
[0179] PD-1-28-z contains the signal sequence domain of PD-1 (1-60nt, NCBI reference sequence: NM_005018.2); the extracellular domain of human PD-1 (61-510nt, NCBI reference sequence: NM_005018.2); the transmembrane domain of human PD-1 (511-525nt, NCBI reference sequence: NM_005018.2); the transmembrane domain derived from human CD28 ( 457-537nt, NCBI reference sequence: NM_006139.2); human CD28-derived intracellular signaling domain (538-660nt, NCBI reference sequence: NM_006139.2); and human CD3z-derived intracellular signaling domain linked to the stop codon TAA (154-492nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2).
[0180] PD-1-4-BB-z is identical to PD-1-28-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the first signaling domain.
[0181] PD-1-30S-z is identical to PD-1-28-z, except that a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain.
[0182] PD-1-28TM is identical to PD-1-28-z, except that it does not contain the first signaling domain or the second signaling domain. [Table 12] The third generation CAR targeting PD-L1
[0183] PD-1-28-30S-z contains the signal sequence domain of human PD-1 (1-60 nt, NCBI reference sequence: NM_005018.2); the extracellular domain of human PD-1 (61-510 nt, NCBI reference sequence: NM_005018.2); the transmembrane domain of human PD-1 (511-525 nt, NCBI reference sequence: NM_005018.2); the transmembrane domain derived from human CD28 (457-537 nt, NCBI reference sequence: NM_006139.2 ); human CD28-derived intracellular signaling domain (538-660 nt, NCBI reference sequence: NM_006139.2); a truncation mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI reference sequence: NM_001243.3); and a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2, codon-optimized) linked to the stop codon TAA.
[0184] PD-1-28-BB-z is identical to PD-1-28-30S-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain.
[0185] PD-1-30S-BB-z is identical to PD-1-28-30S-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain, and an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain. [Table 13] The third generation CAR targeting NKp30
[0186] NKp30-28-30S-z contains the signal sequence domain of human NKp30 (1-54 nt, NCBI reference sequence ID: NM_147130.1); the extracellular domain of human NKp30 (55-405 nt, NCBI reference sequence NM_147130.1); the transmembrane domain derived from human NKp30 (406-420 nt, NCBI reference sequence: NM_147130.1); the transmembrane domain derived from human CD28 (457-537 nt, NCBI reference sequence: NM_0061 39.2); human CD28-derived intracellular signaling domain (538-660 nt, NCBI reference sequence: NM_006139.2); a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI reference sequence: NM_001243.3); and a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI reference sequence: NM_198053.2, codon-optimized) linked to the stop codon TAA.
[0187] NKp30-28-BB-z is identical to NKp30-28-30S-z, except that the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain.
[0188] NKp30-30S-BB-z is identical to NKp30-28-30S-z, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI reference sequence: NM_001243.3) is used as the first signaling domain, and the intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI reference sequence: NM_001561.4, codon optimized) is used as the second signaling domain. [Table 14] Sequence Listing of CARs Described in the Examples and Domains Used in Their Production (mRNA synthesis)
[0189] The above plasmid vector was amplified using the MN NucleoBond Xtra Midi Plus Endotoxin free kit. The amplified plasmid vector was linearized using restriction enzymes. The linearized plasmid was used as a template to produce mRNA by in vitro transcription. The transcription process was performed using the kit (AM1330, AMBION Inc.), followed by DNase treatment, and the final mRNA was produced by 3'polyA tailing using the Poly(A) tailing kit (AM1350, AMBION). After the mRNA was distributed at 40 μg / tube, the concentration and quality were confirmed using the NanoDrop device and the TapeStation device. The mRNA product was stored at -80°C and used for CAR evaluation. (Gene Transfer (Electroporation))
[0190] To introduce the CAR gene into KHYG-1 cells and NK-92 cells, 1×10 7 The cells were centrifuged at 1500 rpm for 3 minutes. After centrifugation, the cells were resuspended in 300 μl of opti-MEM medium. 40 μg of CAR mRNA was added to the cells and electroporated once at 200 V and 2 ms. For αβT cells and γδT cells, the CAR gene was introduced into the same number of cells as above at once under the conditions of 40 μg of mRNA at 380 V and 1 ms. (CAR expression detection)
[0191] To detect the anti-CD19 CAR and anti-EpCAM CAR introduced into NK-92, KHYG-1, αβT and γδT cells, the cells were washed with 4% bovine serum albumin (BSA) buffer and then stained with protein L or human Fab antibody for 30 minutes. At the end of the reaction time, the cells were washed with 4% BSA buffer and fixed with 2% PFA solution. The group stained with protein L was further stained with streptavidin-PE antibody for 25 minutes, then washed with 4% BSA buffer and fixed with 2% PFA solution. For the detection of anti-BCMA CAR, anti-MSLN CAR and anti-GPC3 CAR, rat Fab antibody was used for staining by the same method as above. PD-1CAR was detected using human anti-PD-1 antibody. In addition, NKp30CAR was detected using human anti-NKp30 antibody. The expression rate in stained cells was measured using Aurora (Cytek Biosciences) equipment. (Luciferase-based cytotoxicity)
[0192] 1×10 4 Cells / wells were placed in 96-well plates and made into 50 μl. 50 μl of effector cells introduced with the CAR gene were added at various effector to target (E / T) ratios and reacted in a cell culture incubator at 37 ° C. After four hours of reaction, 100 μl of Bright-Glo solution was added, and the cells were incubated for two minutes with shaking at 500 rpm. After incubation, the reaction solution was fully mixed with a pipette, 100 μl of the reaction solution was transferred to a white opaque 96-well plate, and the fluorescence value was measured at each wavelength using a microplate reader. Cytotoxicity was calculated as follows: specific lysis percentage = 100-target with effector / target only x 100. (Cytokines)
[0193] The target cells were irradiated with 120 Gy of X-rays and 1 × 10 5 Cells / well were placed in a 96-well plate and 100 μl was prepared. 5 Effector cells with the CAR gene introduced were added to cells / well to ensure that the E / T ratio was 1. After the cells were reacted in a cell culture incubator at 37°C for 24 hours, the plate was centrifuged at 1500 rpm for 5 minutes, and 150 μl of supernatant was collected. The amount of secreted cytokines was measured according to the experimental method of the human CD8 / NK multi-analyte flow assay kit (BioLegend, SD, USA). <Experimental Example 1> Evaluation of the cytotoxicity of various immune cells expressing CARs using various types of CD30 domains as co-stimulatory domains against CD19-negative and -positive blood cancer cell lines
[0194] In order to find the best CD30 domain that can increase the anti-tumor efficacy of immune cells as a co-stimulatory domain, the plasmids of the above examples having the structures shown in Table 1 were used to produce the second generation CAR targeting human CD19 antigen and comprising the CD30 domain ( Figure 1a The second generation CARs produced are as follows: CD19-30L-z (1219-1785 nt of CD30 sequence), CD19-30M-z (1501-1785 nt of CD30 sequence), CD19-30M mut -z (1501-1785 nt of CD30 sequence, the 521st amino acid lysine is changed to glutamine, 521K→Q), CD19-30ΔM-z (1501-1785 nt of CD30 sequence, deletion Δ1615-1677 nt, D1615-1677) and CD19-30S-z (1615-1785 nt of CD30 sequence).
[0195] CAR mRNA was introduced into the natural killer cell lines KHYG-1 and NK-92 as well as tαβT cells and γδT cells, and its expression and antitumor efficacy in a variety of immune cells were confirmed.
[0196] CD19-28-z, CD19-30L-z, and CD19-30S-z were highly expressed in all immune cells, but CD19-30M-z, CD19-30M mut -z and CD19-30ΔM-z were barely expressed ( Figure 1c ).
[0197] In the evaluation of cytotoxic efficacy against CD19-negative and -positive blood cancer cell lines, only CD19-28-z and CD19-30S-z specifically killed CD19-positive cancer cell lines ( Figure 1d ).
[0198] Therefore, the present inventors selected CD30S as the optimal co-stimulatory domain and conducted subsequent experiments. <Experimental Example 2> Evaluation of the cytotoxicity of various immune cells expressing CAR using a modified form of the CD30S domain as a co-stimulatory domain against CD19-negative and -positive blood cancer cell lines
[0199] In the above experiments, among the CAR structures containing various types of CD30 domains, only the CAR structure containing CD30S was stably expressed in various immune cells and showed excellent anti-tumor efficacy. In order to facilitate future combination with third-generation CAR using CD30S domain or with interleukin and chemokine receptors, the present inventors produced a smaller form of CD30S domain, namely CD30ΔS, and evaluated its anti-tumor efficacy. Figure 2aAs shown, the cytotoxic efficacy against CD19-positive and negative cancer cell lines was evaluated after CD19-28-z, CD19-30L-z, CD19-30S-z and CD19-CD30ΔS-z (1630-1764 nt of CD30 sequence) mRNA was introduced into αβ T cells and γδ T cells by electroporation.
[0200] CD19-28-z and CD19-30S-z are stably expressed in both αβT cells and γδT cells and exhibit high cytolytic capacity. Although the expression of CD19-CD30ΔS-z in γδT cells is relatively low compared to αβT cells, both cells can effectively kill CD19-positive blood cancer cells ( Figure 2b and 2c ).
[0201] Next, to further improve the function of the CD30ΔS domain, the phosphoinositide 3-kinase binding sites YMNM and YMFM contained in the existing co-stimulatory domains CD28 and ICOS, respectively, were added to CD30ΔS and the anti-tumor efficacy was evaluated. YN -z (1630-1764 nt of CD30 sequence joined to 562-609 nt of CD28 sequence) and CD19-CD30ΔS YF -z (1630-1764nt of the CD30 sequence was connected to 562-609nt of the CD28 sequence, wherein the 193rd amino acid asparagine was changed to phenylalanine, N→F) mRNA was introduced into αβT cells and γδT cells.
[0202] CD19-CD30ΔS YN -z and CD19-CD30ΔS YF -z CARs were stably expressed in αβT cells and γδT cells and demonstrated similar cytotoxic efficacy to T cells introduced with existing CD19-28-z and CD19-30S-z CARs ( Figure 2d and 2e ). <Experimental Example 3> Comparison of cytotoxicity and cytokine secretion ability of αβT cells and γδT cells expressing CAR using CD30S or existing intracellular signaling domain as co-stimulatory domain against CD19 negative and positive blood cancer cell lines
[0203] To determine whether αβT cells and γδT cells expressing CARs using CD30S or existing ICDs (CD28, 4-1BB, CD27, ICOS, OX40) as costimulatory domains specifically kill cancer cells, CD19-28-z, CD19-4-1BB-z, CD19-27-z, CD19-ICOS-z, CD19-OX40-z, and CD19-30S-z CAR mRNAs were introduced into αβT cells and γδT cells by electroporation ( Figure 3a ).
[0204] Except for CD19-ICOS-z and CD19-OX40-z, the remaining CARs are stably expressed in αβT cells and γδT cells. CD19 , IM-9, and Raji, αβT cells and γδT cells expressing CD19-30S-z CAR were confirmed to show similar cytotoxic efficacy as cells expressing CAR containing existing ICD. On the other hand, CAR had no significant effect on the CD19-negative cell line U937. mock Almost no cytolytic activity was shown, similar to the group without the introduction of the CAR gene (NT) ( Figures 3b to 3d ).
[0205] In addition, αβT cells and γδT cells expressing the above-mentioned second-generation anti-CD19 CAR were respectively cultured with CD19-positive U937 CD19 and negative U937 mock The cells were cultured together and the amounts of secreted cytokines IFN-γ, TNF-α, as well as granzyme A, granzyme B, and perforin were measured.
[0206] In αβT cells, CD19-30S-z CAR secreted lower amounts of the above cytokines than CD19-28-z, but similar to CD19-4-1BB-z. On the other hand, for CD19-positive cell lines, in γδT cells, CD19-30S-zCAR secreted lower amounts of IFN-γ and TNF-α than CD19-28-z, but higher amounts than CD19-4-1BB-z. CD19-30S-z secreted similar amounts of granzyme A, granzyme B, and perforin as CD19-28-z ( Figure 3e ). <Experimental Example 4> Comparison of the cytotoxicity and cytokine secretion capacity of αβT cells and γδT cells expressing the third-generation CAR using CD30S as a co-stimulatory domain against CD19-negative and -positive blood cancer cell lines.
[0207] In order to confirm whether αβT cells and γδT cells expressing the third-generation CAR using CD30S as one of the two costimulatory domains and using the existing ICD (CD28, 4-1BB, CD27, ICOS, OX40) as the other react specifically with the antigen, CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-27-z, CD19-30S-ICOS-z and CD19-30S-OX40-z mRNA were produced using the plasmid structures mentioned in the above examples ( Figure 4a ).
[0208] Anti-CD19 third-generation CAR mRNA was introduced into αβT cells and γδT cells by electroporation, and all CARs were stably expressed in αβT cells and γδT cells ( Figure 4b ).
[0209] In addition, similar to the existing CD19-28-BB-z, CARs using CD30S as the co-stimulatory domain (CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-27-z, CD19-30S-ICOS-z, CD19-30S-OX40-z) have been shown to be effective against the CD19-positive cell line U937. CD19 , IM-9 and Raji have specific cytolytic activity. On the other hand, they are effective against the CD19 negative cell line U937 mock No cytolytic activity was shown ( Figure 4c ).
[0210] In addition, αβT cells and γδT cells expressing CD19-28-BB-z, CD19-30S-BB-z, and CD19-28-30S-z CARs were respectively co-cultured with U937 mock and U937 CD19 The cells were cultured together and the amount of cytokine secretion was measured.
[0211] In both αβ T cells and γδ T cells, CD19-30S-BB-z and CD19-28-30S-z CARs using CD30S as a co-stimulatory domain were targeted to CD19-positive U937 cells. CD19 The secreted IFN-γ, TNF-α, granzyme A and granzyme B were higher than those of CD19-28-BB-z( Figure 4d ). <Experimental Example 5> Evaluation of cytotoxicity of γδT cells expressing CAR targeting human BCMA antigen using CD30S as a co-stimulatory domain against human blood cancer cell lines
[0212] To evaluate the efficacy of the CD30S co-stimulatory domain in CARs targeting BCMA expressed in human blood cancers, BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above examples ( Figure 5a ). In addition, the expression of human BCMA was measured in human blood cancer cell lines U937, IM-9, and Daudi. BCMA was not expressed in U937, but BCMA was expressed in IM-9 and Daudi ( Figure 5b ).
[0213] BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z mRNA were introduced into γδT cells using electroporation. BCMA-30S-BB-z and BCMA-28-30S-z containing CD30S were stably expressed in γδT cells, but BCMA-28-BB-z was expressed at very low levels ( Figure 5c γδT cells expressing BCMA-30S-BB-z and BCMA-28-30S-z showed high cytolytic activity against BCMA-positive cell lines IM-9 and Daudi, but showed no cytolytic activity against BCMA-negative cell line U937 ( Figure 5d ). <Experimental Example 6> Evaluation of cytotoxicity of αβT cells and γδT cells expressing CAR targeting human EpCAM antigen using CD30S as a co-stimulatory domain against human solid tumor cell lines
[0214] In order to evaluate the efficacy of the CD30S co-stimulatory domain in CARs targeting EpCAM expressed in human solid tumors, EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z and EpCAM-28TM mRNA were synthesized using the plasmid structures mentioned in the above examples. In addition, the expression of human EpCAM was measured in human lung cancer cell lines A549, Calu-1, NCI-H292 and NCI-H460. The expression of EpCAM in lung cancer cell lines A549, Calu-1, NCI-H292 and NCI-H460 was 70% or more. EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z and EpCAM-28TM mRNA were introduced into αβT cells and γδT cells, respectively, using electroporation ( Figure 6a ).
[0215] EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z and EpCAM-28TM CAR are all highly expressed in αβT cells and γδT cells ( Figure 6b). Although αβT cells and γδT cells expressing EpCAM-28-z, EpCAM-4-1BB-z, and EpCAM-30S-z were evaluated to have similar cytolytic activity against lung cancer cell lines expressing EpCAM, the group without CAR introduction and the group with EpCAM-28TM introduction did not show cytolytic activity ( Figure 6c and 6d ).
[0216] In addition, to evaluate the efficacy of the CD30S co-stimulatory domain in the third-generation CAR targeting EpCAM, EpCAM-28-BB-z, EpCAM-30S-BB-z, and EpCAM-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above examples and introduced into αβT cells and γδT cells, respectively ( Figure 6e ).
[0217] EpCAM-28-BB-z, EpCAM-30S-BB-z, and EpCAM-28-30S-z are all stably expressed in αβT cells and γδT cells ( Figure 6f ). αβT cells introduced with the third-generation EpCAM CAR were evaluated as having excellent cytotoxic effects against A549, Calu-1, NCI-H292, and NCI-H460. In γδT cells, EpCAM CAR also effectively killed EpCAM-positive lung cancer cell lines ( Figure 6g ). <Experimental Example 7> Evaluation of cytotoxicity of αβT cells and γδT cells expressing CAR targeting human mesothelin antigen using CD30S as a co-stimulatory domain against human solid tumor cell lines
[0218] To evaluate the efficacy of the CD30S costimulatory domain in CARs targeting mesothelin expressed in human solid tumors, the expression of human mesothelin was measured in human lung cancer cell lines A549 and NCI-H292, human pancreatic cancer cell line AsPC-1, and human ovarian cancer cell line SKOV3. Mesothelin is highly expressed in lung cancer cell line NCI-H292 and pancreatic cancer cell line AsPC-1, and is expressed at lower levels in lung cancer cell line A549 and ovarian cancer cell line SKOV3 ( Figure 7b ). The plasmid structures mentioned in the above examples were used to synthesize MSLN-28-z, MSLN-4-1BB-z, and MSLN-30S-z mRNAs, which were introduced into αβT cells and γδT cells, respectively ( Figure 7a ).
[0219] The above-mentioned second-generation anti-mesothelin CARs are highly expressed in both αβT cells and γδT cells ( Figure 7c). αβT cells and γδT cells introduced with MSLN-28-z and MSLN-4-1BB-z CARs were confirmed to be cytotoxic only against mesothelin-positive NCI-H292 and AsPC-1. αβT cells and γδT cells introduced with MSLN-30S-z CARs were evaluated to have slightly lower cytotoxic efficacy than cells introduced with MSLN-28-z and MSLN-4-1BB-z CARs. It was confirmed that MSLN-28-z, MSLN-4-1BB-z, and MSLN-30S-z CARs all showed cytotoxicity only against cell lines expressing mesothelin ( Figure 7d ).
[0220] In addition, in order to evaluate the efficacy of the CD30S co-stimulatory domain in the third-generation CAR targeting mesothelin, MSLN-28-BB-z, MSLN-30S-BB-z and MSLN-28-30S-z mRNA were synthesized using the plasmid structures mentioned in the above examples and introduced into αβT cells and γδT cells, respectively, using electroporation ( Figure 7e ). MSLN-28-BB-z, MSLN-30S-BB-z, and MSLN-28-30S-z CARs are highly expressed in αβT cells and γδT cells ( Figure 7f ). Except for the NT group, the rest of the MSLN-CARαβT cells only showed cytolytic activity against NCI-H292, but not against AsPC-1, SKOV3, and A549. In γδT cells, the anti-mesothelin third-generation CAR only selectively killed NCI-H292 and AsPC-1 (which highly expressed mesothelin) Figure 7g ). <Experimental Example 8> Cytotoxicity of γδT cells expressing CAR targeting human GPC3 antigen using CD30S as a co-stimulatory domain against human solid tumor cell lines
[0221] To evaluate the efficacy of the CD30S co-stimulatory domain in CARs targeting GPC3 expressed in human solid tumors, GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above examples ( Figure 8a ). The expression of human GPC3 was measured in the human liver cancer cell line HepG2 and the human lung cancer cell lines NCI-H292 and A549. GPC3 was expressed in the liver cancer cell line HepG2, but not in the lung cancer cell lines NCI-H292 and A549 ( Figure 8b ).
[0222] GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z mRNA were introduced into αβT cells and γδT cells, respectively, by electroporation. GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z CARs were stably expressed in γδT cells ( Figure 8c ). γδT cells expressing GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-zCAR were confirmed to have specific cytolytic activity only against the GPC3-positive cell line HepG2, but not against the negative cell lines NCI-H292 and A549 ( Figure 8d ). <Experimental Example 9> Evaluation of cytotoxicity of αβT cells and γδT cells expressing CAR targeting human PD-L1 antigen using CD30S as a co-stimulatory domain against human solid tumor cell lines
[0223] To evaluate the efficacy of the CD30S co-stimulatory domain in CAR targeting PD-L1 expressed by human solid tumors, PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z and PD-1-28TM mRNAs were synthesized using the plasmid structures mentioned in the above examples ( Figure 9a ). The expression of human PD-L1 was measured in lung cancer cell lines NCI-H292 and Calu-1, pancreatic cancer cell line AsPC-1, and head and neck cancer cell line FaDu. PD-L1 was highly expressed in all cell lines ( Figure 9b ). PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM mRNA were introduced into αβT cells and γδT cells respectively by electroporation. PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM CAR were all highly expressed in αβT cells and γδT cells ( Fig.9c ). In αβT cells, except for NT and PD-1-28TM CAR T cells, CARs only showed cytolytic activity against NCI-H292 and Calu-1. On the other hand, in γδT cells, the above CARs (PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z) selectively killed NCI-H292, Calu-1, and FaDu. All PD-1CARs did not show cytolytic activity against the PD-L1-positive cell line AsPC-1 ( Figure 9d ).
[0224] In addition, to evaluate the efficacy of the CD30S co-stimulatory domain in the third-generation CAR targeting PD-L1, PD-1-28-BB-z, PD-1-30S-BB-z, PD-1-28-30S-z mRNA were synthesized using the plasmid structure mentioned in the above example and then introduced into γδ T cells using electroporation ( Fig.9e PD-1-28-BB-z, PD-1-30S-BB-z, and PD-1-28-30S-zCAR are all highly expressed in γδT cells ( Figure 9f ). Similar to the cytotoxicity test results of γδT cells introduced with the second-generation PD-1 CAR, γδT cells introduced with the third-generation PD-1 CAR selectively killed NCI-H292, Calu-1, and FaDu, but showed no cytotoxic activity against AsPC-1 ( Figure 9g ). <Experimental Example 10> Evaluation of cytotoxicity of αβT cells and γδT cells expressing CAR targeting human B7-H6 antigen using CD30S as a co-stimulatory domain against human solid tumor cell lines
[0225] To evaluate the efficacy of the CD30S co-stimulatory domain in CARs targeting B7-H6 expressed in human solid tumors, NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above examples ( Fig.10a The expression of human B7-H6 was measured in human lymphoma cell lines U937 and K562, human Burkitt lymphoma cell line Raji, and human lung cancer cell line A549. In A549, B7-H6 was not expressed, while in U937, Raji, and K562, B7-H6 was expressed by 70% or more ( Fig.10b ).
[0226] Electroporation was used to introduce NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z mRNA into αβT cells and γδT cells, respectively. NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-zCARs were stably expressed in αβT cells and γδT cells ( Fig.10c ). αβT cells and γδT cells expressing NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z CARs were confirmed to have specific cytolytic activity against B7-H6 positive cell lines U937, Raji, and K562, but not against negative cell line A549 ( Fig.10d ). <Experimental Example 11> Therapeutic anti-tumor effect of T cells expressing second-generation CD19-CAR based on the combination of CD30S and existing ICD (CD28, 4-1BB) in the human leukemia cell line NALM6 xenograft animal model
[0227] The anti-tumor activity evaluation and testing methods of T cells expressing the second-generation CD19-CAR are as follows. (mouse, cell lines)
[0228] Six-week-old female NOD / Shi-scid IL2rgamma(null) (NOG, NOD.Cg-Prkdc scid Il2rgtm1sug / JicKoat) mice were purchased from Koatech Inc. (Pyeongtaek, Kyunggi) and housed under sterile conditions in the animal laboratory of the Catholic University of Korea. All procedures in animal studies were performed in accordance with the guidelines and policies for rodent experimentation and the care and use of laboratory animals provided by the Institutional Animal Care and Use Committee (IACUC) of the Catholic University of Korea College of Medicine in Seoul (approval number: CUMS-2022-0285-02) and the Laboratory Animal Welfare Act. NALM6 cells were purchased from the American Type Culture Collection (Manassas, VA), and all cell lines were cultured according to the manufacturer's recommendations. (Evaluation of therapeutic anti-tumor effects)
[0229] To evaluate the in vivo therapeutic effect, 1×10 6 NALM-6-luc-thy1.1 cells were intravenously administered into the tail of mice, and then 1 × 10 7 CD19-CAR-αβT cells were administered once. Mice that did not receive cell therapy (no treatment) were included as a control group. Tumor growth over time was monitored by in vivo bioluminescence imaging in individual mice, and animal weights were measured at fixed times. Mice that lost 20% or more of their body weight were euthanized according to approved laboratory animal protocols.
[0230] Tumor growth was monitored over time by detecting bioluminescence in the whole animal using an in vivo imaging system (IVIS) Lumina x-ray multi-species optical imaging system (XRMS) (in vivo luminescent bioimaging). Luciferin (Promega, P1043) was prepared to 15 mg / mL using a sterile saline solution, stored in a -80°C refrigerator, and thawed at 37°C before use. To confirm bioluminescence, mice received an intraperitoneal injection of 3 mg / 200 μl luciferin and were allowed a reaction time of seven to eight minutes. After the reaction time, the mice were anesthetized throughout the imaging process through a nose cone isoflurane oxygen delivery device, and bioluminescence was measured in a light-tight chamber. In the tumor growth image analysis, the evaluation was performed by quantifying the average luminescence of bioluminescence in individual mice.
[0231] like Fig.11a and 11b As shown, an animal model of xenograft human leukemia cell line NALM6 was established to evaluate the in vivo efficacy of αβT cell therapy transduced using CD30S targeting CD19 or second-generation CAR used as an existing co-stimulatory domain. The results showed that compared with untransduced αβT cell therapy, the anti-tumor effects of CD19-28-z, CD19-4-1BB-z, and CD19-30S-z CAR-αβT cells all showed therapeutic benefits of delaying tumor growth and improving survival. Among them, the CD19-30S-z CAR-αβT cell treatment group had a significantly higher anti-tumor effect than the CD19-28-z, CD19-4-1BB-z, and CAR-αβT cell treatment groups, and no significant toxicity was observed.
[0232] The present invention can be used as immune cell therapy in the field of tumor treatment.
Claims
1. A chimeric antigen receptor, comprising: target antigen binding domain; transmembrane domain; A C30-derived intracellular signaling domain comprising one or more amino acid sequences selected from the group consisting of SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, and SEQ ID NO:50; and CD3ζ intracellular signaling domain.
2. The chimeric antigen receptor according to claim 1, wherein The target antigen binding domain comprises an antibody or a fragment thereof that specifically binds to a target antigen.
3. The chimeric antigen receptor according to claim 1, wherein The target antigen is selected from the group consisting of: CD19, MUC16, MUC1, CAIX, CEA, CDS, CD7, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, BCMA, PD-1, NKp30, cytomegalovirus (CMV) infected cell antigen, EGP-2, EGP-40, EpCAM, Erb-B2, Erb-B3, Erb-B4, FBP, fetal acetylcholine receptor, folate receptor- α, GD2, GD3, HER-2, hTERT, IL-13R-α2, κ-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, NKG2D ligand, NY-ESO-1, carcinoembryonic antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, CD24, CD47, EGFR, CD123, GPC3, CD117, Claudin18.2, cMET, EphA2, CLL-1, CD171, AXL, ROR2, FAP, and CD5.
4. The chimeric antigen receptor according to claim 1, wherein The transmembrane domain is a transmembrane domain of a TCR co-receptor or a T cell co-stimulatory molecule selected from the group consisting of: CD8, 4-1BB, CD27, CD28, CD30, OX40, CD3e, CD3ζ, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154 and ICOS (CD278), or derived therefrom.
5. The chimeric antigen receptor according to claim 1, wherein The chimeric antigen receptor further comprises a hinge region located between the C-terminus of the target antigen binding domain and the N-terminus of the transmembrane domain.
6. The chimeric antigen receptor according to claim 1, wherein The chimeric antigen receptor further comprises an intracellular signaling domain selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40 and KIR2DS2.
7. The chimeric antigen receptor according to claim 1, wherein The chimeric antigen receptor further comprises a signal peptide located at the N-terminus of the target antigen binding domain, wherein the signal peptide is selected from the group consisting of: a GM-CSF receptor signal sequence, a CD8α signal sequence, an immunoglobulin heavy chain signal sequence, a PD-1 signal sequence, and a NKp30 signal sequence.
8. A nucleic acid molecule encoding the chimeric antigen receptor according to claim 1.
9. A vector comprising the nucleic acid molecule according to claim 7.
10. An isolated immune effector cell comprising the chimeric antigen receptor according to claim 1, the nucleic acid molecule according to claim 8 or the vector according to claim 9.
11. The immune effector cell according to claim 10, wherein The immune effector cells are αβT cells, γδT cells, NK cells, NK T cells or macrophages. 12 . An anti-tumor composition comprising the immune effector cell according to claim 10 .
13. A method for treating cancer, comprising administering a therapeutically effective amount of the immune effector cell according to claim 10 to a subject in need thereof.
14. The method for treating cancer according to claim 13, wherein: The cancer is selected from lung cancer, colorectal cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, melanoma, retinoblastoma, thymic cancer, stomach cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, lymphoma, leukemia or multiple myeloma.
